Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

Item
http://www.wikidata.org/entity/Q33977187
Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance studyAbacavir and metabolite pharmacokinetics in HIV-1-infected children and adolescents.Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adultsPopulation pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma.Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors.High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothersPilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes.Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults.The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cellsAcute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.Development and characterization of a long-acting nanoformulated abacavir prodrugZidovudine impairs adipogenic differentiation through inhibition of clonal expansion.
P2860

Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection

Item
http://www.wikidata.org/entity/Q33977187
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Single-dose pharmacokinetics a ...... munodeficiency virus infection
@ast
Single-dose pharmacokinetics a ...... munodeficiency virus infection
@en
type
label
Single-dose pharmacokinetics a ...... munodeficiency virus infection
@ast
Single-dose pharmacokinetics a ...... munodeficiency virus infection
@en
prefLabel
Single-dose pharmacokinetics a ...... munodeficiency virus infection
@ast
Single-dose pharmacokinetics a ...... munodeficiency virus infection
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932
P356
P1433
P1476
Single-dose pharmacokinetics a ...... munodeficiency virus infection
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P932